Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 16, 2016

Primary Completion Date

July 28, 2021

Study Completion Date

July 28, 2021

Conditions
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate Cancer
Interventions
RADIATION

stereotactic radiosurgery

Undergo MRI-guided focal SRS

DEVICE

magnetic resonance imaging

Undergo staging MRI with contrast

OTHER

quality-of-life assessment

Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time

PROCEDURE

Serum Prostate Antigen Test

Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.

PROCEDURE

Digital Rectal Exam

Exam of rectal health. Performed every three months for up to two years throughout the study.

BEHAVIORAL

Expanded Prostate Cancer Index Composite

This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.

Trial Locations (1)

44106-5065

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT02163317 - Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer | Biotech Hunter | Biotech Hunter